China's Second-largest CRO Seeks Initial Public Offering In The U.S.
This article was originally published in PharmAsia News
Executive Summary
Seeking to join top competitor WuXi PharmaTech on the New York Stock Exchange, ShangPharma, the second-largest contract research organization in China, is looking to raise an estimated $89.9 million in an initial public offering expected to debut the week of Oct. 18